1. Home
  2. SAIA vs NBIX Comparison

SAIA vs NBIX Comparison

Compare SAIA & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saia Inc.

SAIA

Saia Inc.

HOLD

Current Price

$359.97

Market Cap

11.2B

Sector

Industrials

ML Signal

HOLD

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$162.00

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAIA
NBIX
Founded
1924
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2B
13.2B
IPO Year
2002
1996

Fundamental Metrics

Financial Performance
Metric
SAIA
NBIX
Price
$359.97
$162.00
Analyst Decision
Buy
Strong Buy
Analyst Count
19
22
Target Price
$391.06
$180.91
AVG Volume (30 Days)
487.9K
1.3M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
41.95
EPS
5.37
3.30
Revenue
$3,234,286,000.00
$161,626,000.00
Revenue This Year
$7.29
$24.73
Revenue Next Year
$9.08
$13.14
P/E Ratio
$69.71
$50.32
Revenue Growth
0.79
977.51
52 Week Low
$249.32
$122.14
52 Week High
$494.71
$186.12

Technical Indicators

Market Signals
Indicator
SAIA
NBIX
Relative Strength Index (RSI) 33.15 40.24
Support Level $357.64 $153.96
Resistance Level $376.30 $169.57
Average True Range (ATR) 16.81 6.37
MACD -5.69 -2.08
Stochastic Oscillator 20.99 0.64

Price Performance

Historical Comparison
SAIA
NBIX

About SAIA Saia Inc.

Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 210 facilities and a fleet of more than 7,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Share on Social Networks: